Prohibition Partners
Home / Reports & Data / The Asian Cannabis Report: 2nd Edition
ReportAsia

The Asian Cannabis Report: 2nd Edition

In this report, Prohibition Partners and Teera Group explore the regulations and market developments in the most populous continent in the world.

  • Analyst-written market analysis
  • PDF + data
  • Published 2022

Cited in boardrooms, legal proceedings & government briefings since 2017. Our figures are built to be defended — sourced, modelled and signed off by PP’s analysts.

Trusted by teams at

DIAGEOKPMGBarclaysNovartisBloomberg

About this edition

In this report, Prohibition Partners and Teera Group explore the regulations and market developments in the most populous continent in the world. It combines PP’s proprietary market sizing with regulatory analysis, giving investors and corporates a single, citable reference — delivered digitally, licensed for internal use, and backed by the analysts who built the numbers.

PDF + data

delivery format

2022

published

Inside this edition

Overview

Cannabis is undergoing a process of re-liberalisation in Asia, where the damaging drug control policies, which have been pushed for decades, are receding in favour of more sensible, supportive and economically sound policies. While full legalisation is underway across much of North America and Europe, the legalisation of cannabis and its derivatives is occurring more gradually in Asia. The health and financial benefits of cannabis legalisation in North America are serving as an example to governments in Asia, and across the world, that the prohibition of cannabis is no longer a politically justifiable position to maintain. This is convincing more and more governments in Asia to reapraise their national drug strategies. COVID-19 was a catalyst for cannabis adoption during the pandemic, with countries, such as India noting increased usage among its citizens to combat stress and anxiety during challenging times. Cannabis is also seen as a new economic opportunity for many countries following the global lockdown, when the economy, exports and travel were brought to a standstill. Cannabis promises a brand new industry which will generate billions of dollars for several countries in the world in the near future. While this opportunity exists now, competition from many regions is increasing, and countries seeking to export, need to carefully consider the number of competitors, as well as supply and demand balances in target markets. Thailand is at the leading edge of cannabis liberalisation in South East Asia. The region decriminalised medical cannabis in 2018 and the country then decriminalised cannabis plant parts in a push towards commercialisation in June 2022. For a full exploration of cannabis liberalisation in Asia in Thailand see the Business In-sights into the Thai Cannabis Market Report available alongside this report.

Contents16
  • Medicinal cannabis
  • CBD and Consumer Products
  • Hemp
  • Cultural zeitgeist
  • Commercial opportunities
  • Challenges
  • Expert Interviews
  • Michelle Wilder & Luc Richner, Cannavigia
  • Dr Anunchai Assawamakin, Ministry of Public Health
  • Dr Pakakrong Kwankao, Chao Phya Abhaibubejhr Hospital
  • Nadon Chaicharoen, TEERA Group
  • Nuntakan Suwanpidokkul, Government Pharmaceutical Organisation
  • Jahan Peston Jamas, BOHECO
  • Toshihiko Ito, Japan Cannabidiol Association
  • Yen-Ho Lai (Dr Kiang), Cannabis Advocate
  • Andrew Lee, CBD Lab Asia
Key findings8
  • While countries such as India, South Korea, China and Japan still face regulatory hurdles from their respective governments, there are burgeoning opportunities for commercialisation in exports and even loopholes that allow for certain businesses to operate and thrive.
  • Cannabis has long held a place in traditional Asian medicine. The region itself is heavily influenced by its large Hindu and Buddhist religions, all of which have integrated the traditional use of cannabis to some extent, particularly in healing and medical usage.
  • Cannabis CBD infused products have seen a sharp increase in demand in Asia, reflecting shifting attitudes and demands from consumers.
  • Hemp is an industry and stands on its own in countries across Asia, with a long history of usage dating back millennia.
  • The general attitude regarding cannabis, CBD and hemp is changing rather significantly across Asia, and the industry is gaining momentum from the public, as more people recognise its various uses and benefits.
  • Business opportunities are increasing in tandem with the rise of interest in cannabis in Asia. From opportunities in medical tourism, wellness and mental health treatments, more businesses are seeing the commercial value in cannabis- driven businesses.
  • Regulatory roadblocks, laws and government policies are key barriers to the cannabis industry in Asia. No Asian country has formally legalised cannabis for recreational purposes.
  • The cannabis industry in Asia has significant untapped commercial potential, together with deeply rooted historical uses of hemp and cannabis variations; the region is shaping up to be a unique and exciting landscape.

Who it’s for

Investors & analysts

Defensible sizing and forecasts to underwrite the thesis.

Corporate strategy & FMCG

Opportunity sizing and entry routes across key markets.

More from the library

All research